Sangamo Therapeutics Inc
NASDAQ:SGMO
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
Fabry Program Progress: Sangamo presented promising clinical data for ST-920 in Fabry disease, with FDA reaffirming use of eGFR slope as the accelerated approval endpoint and a BLA submission planned as early as Q1 2026.
Neurology Pipeline: Patient enrollment began in the Phase I/II STAND study for chronic neuropathic pain with ST-503, and the first patient is expected to be dosed in the coming months.
Prion Disease Program: Prion program (ST-506) advancing toward a clinical trial application submission by mid-2026, with encouraging preclinical results and ongoing regulatory engagement.
Financial Runway: Cash and cash equivalents are expected to fund operations into the first quarter of 2026 following a $6 million payment from Pfizer and ongoing cost controls.
Business Development: Active discussions for a Fabry commercialization partnership continue, supported by regulatory clarity; additional business development opportunities are being pursued across the pipeline.
Regulatory Engagement: Management expressed strong confidence in regulatory clarity and process with the FDA, with no outstanding major questions for Fabry or neurology programs.
